CDK4 and breast cancer: The PI3K-PDK1 signaling pathway has been implicated in mediating resistance to CDK4/6 inhibitors, with ribociclib-resistant BC cell lines demonstrating an increase in PDK1 levels following drug exposure, resulting in activation of the AKT pathway (37).